Today, major cryptocurrencies are in the red the day after Fed Chair Powell says another rate cut in December is not a foregone conclusion. JP Morgan says Circle USDC is outpacing Tether's USDT in onchain activity. And Canary Capital CEO Steven McClur breaks down how the asset manager's new spot crypto ETFs tied to Litecoin and Hyera are performing.Welcome to CNBC's Crypto World. I'm Katie Terasv. Major cryptocurrencies pointed lower one day after Fed Chair Jay Powell suggested the central bank may not cut ...

JPMorgan executes first fund-servicing transaction on its Kinexys blockchain https://t.co/pgH1Z4QIG5 ...

BREAKING: 🇺🇸 $4.6T JPMorgan CEO Jamie Dimon admits he was wrong and crypto is “real.” He said stablecoins will be used by all major banks to facilitate better transactions. https://t.co/5KSDBfYn8M ...

JUST IN: JPMorgan to launch investment fund tokenization platform in 2026. ...

Group 1 - Constellation Energy Corporation (NASDAQ:CEG) is recognized as a promising stock to buy, with analysts raising price targets significantly [1][3] - Mizuho analyst Anthony Crowdell increased the price target for Constellation Energy to $390 from $335 while maintaining a Neutral rating [1] - Wells Fargo initiated coverage with an Overweight rating and a price target of $478, citing rising momentum driven by near-term catalysts and a favorable supply-demand dynamic in the power market [2] Group 2 - JPMorgan also raised its price target for Constellation Energy to $422 from $391, keeping an Overweight rating ahead of the company's Q3 2025 earnings report [3] - Constellation Energy operates in the US energy market, providing products and services across five segments: Mid-Atlantic, Midwest, New York, ERCOT, and Other Power Regions [4]

Core Insights - Diamond Hill Capital's "Select Fund" underperformed the Russell 3000 Index in Q3 2025, returning 4.98% compared to the index's 8% gain [1] - The fund initiated four new positions in Q3, including Colgate-Palmolive Company, indicating a belief in the long-term growth potential of certain undervalued companies [3] Company Performance - Colgate-Palmolive Company (NYSE:CL) experienced a one-month return of -2.91% and a 52-week loss of 18.86%, closing at $75.73 per share with a market capitalization of $61.207 billion on October 29, 2025 [2] - Despite the overall market rally, Colgate-Palmolive's stock is not among the top 30 most popular stocks among hedge funds, with 59 hedge fund portfolios holding it at the end of Q2 2025, down from 65 in the previous quarter [4] Investment Outlook - JPMorgan has cut Colgate-Palmolive's price target to $88 while maintaining an overweight rating, suggesting a cautious but positive outlook [4] - The investment community acknowledges Colgate-Palmolive's potential but sees greater upside in certain AI stocks, indicating a competitive investment landscape [4]

Group 1 - Ares Capital Corporation (NASDAQ:ARCC) is highlighted as a trending investment opportunity despite concerns in the credit markets [2] - Bryn Talkington, Managing Partner of Requisite Capital Management, supports buying ARCC, referencing JPMorgan CEO Jamie Dimon's warnings about potential credit risks [2] - Talkington notes that ARCC and Blue Owl are trading 8% to 10% below book value, with expected yields around 10%, indicating potential for a 20% total return in the next year [2] Group 2 - The article mentions that while ARCC is a potential investment, there are AI stocks that may offer higher returns with limited downside risk [3] - A free report is suggested for those interested in an extremely cheap AI stock that benefits from Trump tariffs and onshoring [3]

RT CoinDesk (@CoinDesk)🗽The world’s financial elite are heading to NYC for @Ripple Swell.Over 700 of the world's most influential voices—including leaders from NASDAQ, BlackRock, JPMorgan, and global policy will convene at this two-day gathering.Tune into @CoinDesk Live on November 4th & 5th from 9:30a.m. -12:00 p.m. ET! ...

🗽The world’s financial elite are heading to NYC for @Ripple Swell.Over 700 of the world's most influential voices—including leaders from NASDAQ, BlackRock, JPMorgan, and global policy will convene at this two-day gathering.Tune into @CoinDesk Live on November 4th & 5th from 9:30a.m. -12:00 p.m. ET! ...

Group 1 - Kenvue Inc. (NYSE:KVUE) is considered a stock with significant upside potential despite recent price target reductions by major banks [1][2] - Deutsche Bank lowered its price target for Kenvue to $18 from $20 while maintaining a Hold rating [1][2] - JPMorgan also reduced its price target for Kenvue to $21 from $24, keeping an Overweight rating, citing a weak outlook for large-cap companies in the household and personal care sector [1][2] Group 2 - The consumer health company operates in multiple regions including the US, Europe, the Middle East, Africa, Asia-Pacific, and Latin America [3] - Kenvue's business segments include Self Care, Skin Health & Beauty, and Essential Health [3]